Last reviewed · How we verify
Bortezomib (B)
Bortezomib inhibits the 26S proteasome, preventing the degradation of proteins that regulate cell cycle and apoptosis, leading to cancer cell death.
Bortezomib inhibits the 26S proteasome, preventing the degradation of proteins that regulate cell cycle and apoptosis, leading to cancer cell death. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Mantle cell lymphoma, Light chain myeloma.
At a glance
| Generic name | Bortezomib (B) |
|---|---|
| Also known as | Velcade |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | Proteasome inhibitor |
| Target | 26S proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Bortezomib is a reversible proteasome inhibitor that blocks the degradation of ubiquitinated proteins, causing accumulation of pro-apoptotic factors and cell cycle inhibitors. This leads to G2/M phase arrest and triggers apoptosis in cancer cells, particularly in multiple myeloma and mantle cell lymphoma. The drug is especially effective in hematologic malignancies where proteasome inhibition disrupts the balance of survival and death signals.
Approved indications
- Multiple myeloma (newly diagnosed and relapsed/refractory)
- Mantle cell lymphoma
- Light chain myeloma
Common side effects
- Peripheral neuropathy
- Thrombocytopenia
- Neutropenia
- Anemia
- Nausea
- Diarrhea
- Fatigue
- Herpes zoster reactivation
Key clinical trials
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (PHASE1)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (PHASE1, PHASE2)
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (PHASE3)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bortezomib (B) CI brief — competitive landscape report
- Bortezomib (B) updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI